about
The epigenetic landscape of acute myeloid leukemiaJNK signalling in cancer: in need of new, smarter therapeutic targetsEpigenetic Guardian: A Review of the DNA Methyltransferase DNMT3A in Acute Myeloid Leukaemia and Clonal Haematopoiesis.Lessons in platelet production from inherited thrombocytopenias.Bleeding is not the main clinical issue in many patients with inherited thrombocytopaenias.Ras-induced epigenetic inactivation of the RRAD (Ras-related associated with diabetes) gene promotes glucose uptake in a human ovarian cancer model.Rapid detection of DNMT3A R882 mutations in hematologic malignancies using a novel bead-based suspension assay with BNA(NC) probesAdvances in treating acute myeloid leukemia.Detection of acquired hemoglobinopathy in children with hematological malignancies at disease onset: results form a national referral centre.Alteration of the SETBP1 gene and splicing pathway genes SF3B1, U2AF1, and SRSF2 in childhood acute myeloid leukemiaNovel multiplex bead-based assay for detection of IDH1 and IDH2 mutations in myeloid malignancies.The long noncoding RNA HOTAIR contributes to cisplatin resistance of human lung adenocarcinoma cells via downregualtion of p21(WAF1/CIP1) expressionAcute myeloid leukemia: survival analysis of patients at a university hospital of Paraná.Incidences and Prognostic Impact of c-KIT, WT1, CEBPA, and CBL Mutations, and Mutations Associated With Epigenetic Modification in Core Binding Factor Acute Myeloid Leukemia: A Multicenter Study in a Korean PopulationCharacterization of miRNomes in acute and chronic myeloid leukemia cell lines.The prognostic impact of mutations in spliceosomal genes for myelodysplastic syndrome patients without ring sideroblastsPharmacodynamic assays to facilitate preclinical and clinical development of pre-mRNA splicing modulatory drug candidates.Epigenetic Role of Histone 3 Lysine Methyltransferase and Demethylase in Regulating Apoptosis Predicting the Recurrence of Atypical MeningiomaRadiation Induced Apoptosis of Murine Bone Marrow Cells Is Independent of Early Growth Response 1 (EGR1).Oncogene- and drug resistance-associated alternative exon usage in acute myeloid leukemia (AML).Acute myeloid leukemia in the era of precision medicine: recent advances in diagnostic classification and risk stratification.Molecular similarity between myelodysplastic form of chronic myelomonocytic leukemia and refractory anemia with ring sideroblastsCTNNA1 hypermethylation, a frequent event in acute myeloid leukemia, is independently associated with an adverse outcomeAcquired ASXL1 mutations are common in patients with inherited GATA2 mutations and correlate with myeloid transformation.FLT3 inhibitors: clinical potential in acute myeloid leukemia.CD64-directed microtubule associated protein tau kills leukemic blasts ex vivo.Mouse models of NPM1-mutated acute myeloid leukemia: biological and clinical implications.Mutations of c-Cbl in myeloid malignanciesMolecular Malfeasance Mediating Myeloid Malignancies: The Genetics of Acute Myeloid Leukemia.Autophagy regulated by lncRNA HOTAIR contributes to the cisplatin-induced resistance in endometrial cancer cells.Molecular characterization of EZH2 mutant patients with myelodysplastic/myeloproliferative neoplasms.Kefir induces apoptosis and inhibits cell proliferation in human acute erythroleukemia.Significance of ETV6 rearrangement in acute promyelocytic leukemia with t(15;17)/promyelocytic leukemia/retinoic acid receptor alpha.Genetic variants involved in oxidative stress, base excision repair, DNA methylation, and folate metabolism pathways influence myeloid neoplasias susceptibility and prognosis.Iron-induced epigenetic abnormalities of mouse bone marrow through aberrant activation of aconitase and isocitrate dehydrogenase.RASSF1A hypermethylation is associated with ASXL1 mutation and indicates an adverse outcome in non-M3 acute myeloid leukemia.Optimization of antitumor modulators of pre-mRNA splicing.[Myelodysplastic syndromes. Epidemiology, molecular and morphological characteristics and risk stratification].Identification of target genes using gene expression profile of granulocytes from patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.PRC2 dysfunction through multiple mechanisms in myeloid malignancies.
P2860
Q21284742-7CD28C92-BDE5-4C19-9614-993A3DF81740Q27023869-AAB64168-4DF4-4E50-B90A-7A1D40A5395FQ30235316-2799A94E-094A-4477-AC04-D223C32DF9D5Q33413048-C637AB95-9CBD-4057-9FB2-2E662CECD948Q33442532-B04E3FC5-5E77-4462-8FBB-34B86196C3FCQ33619509-A28BA773-9FD8-4335-90E9-306D6044E6A9Q33734576-22105118-B919-46AF-BFC8-E6A4A8BD0505Q34312351-CCCB26F5-DD35-4611-BA12-2BA55C722EC2Q34375577-94C39FFE-6834-4BBF-9F35-4E9F574F365CQ34749589-F29C5E91-0AC2-4931-9B02-15D7EFD62335Q35010433-D3235A1C-CA93-4A4A-90A9-D99538764429Q35025421-F9B7AA9F-8A4E-4BE3-86B6-BB4AA51DE9ABQ35054850-ABF5F27C-D4A8-433F-82AF-5D21B381AEA8Q35332017-8DC59B20-3F62-41E7-876E-3D6312C11438Q35543478-999D9C28-CA8C-449E-9E54-73E78BEDB491Q35675958-A74AE441-1558-462C-B960-DF4EB00E5524Q35822289-D1F9CACD-0A88-4EEF-846E-84ABF68D8BD8Q35905146-9BE7B448-2D4A-4C70-A2B2-5A1A855582A1Q36247578-CA4D471F-C094-4F1D-8FCB-D3307F3F8544Q36771977-8C8A14A7-8229-4C22-8A97-A8208A61E129Q36849666-359BE19D-BA70-489B-AEC4-D9BF528F7379Q36936451-2E3EC845-1A09-4A61-8A73-A74528DACBAFQ37327786-3B99A54D-BCFF-49CC-BE01-F8FE002544CFQ37552020-DD6EFA17-2E7C-4918-AEB7-E3B0C37AF000Q37638749-FBC5DB20-CDE8-40A0-84E4-E9CDB0523E28Q37687139-4EE117FE-8234-479A-8068-F06F578B8957Q38245417-F1220CCA-A70F-4A86-9DFB-E1CF18F5F39AQ38509939-B7A85DC5-18EA-48C4-890F-939D160428E6Q38653160-0516F3D0-A959-44C3-B4AB-A5D5E0C6B4C2Q38696862-13D7E635-3E76-4A3A-AFB6-BF045821607EQ38699939-B32C6793-2769-4313-8429-6EFEB53D3B7DQ38808744-D8C23C06-BAE4-4109-A278-62CD96C2AACFQ38851852-28E72B72-DE39-4D37-B804-EB0889B9B281Q39942266-643496A3-733F-4DE6-8AD9-A018AB0333C1Q40387078-D6657D2B-E51C-442D-8026-5D3D1DC43CDBQ41545370-8CD803FB-5F93-4316-B036-70D7C794DBCEQ41973693-FD57F303-8DAD-4FD1-9245-31B504807C98Q44325617-F45ACE72-B1BB-4B02-982C-53D5A88592FFQ44484646-8199D5A3-BAA5-4B98-89E5-158B303F0979Q45244422-E23E570C-54C6-487A-A152-AFE69565C070
P2860
description
2012 nî lūn-bûn
@nan
2012 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Myeloid malignancies: mutations, models and management
@ast
Myeloid malignancies: mutations, models and management
@en
Myeloid malignancies: mutations, models and management
@nl
type
label
Myeloid malignancies: mutations, models and management
@ast
Myeloid malignancies: mutations, models and management
@en
Myeloid malignancies: mutations, models and management
@nl
prefLabel
Myeloid malignancies: mutations, models and management
@ast
Myeloid malignancies: mutations, models and management
@en
Myeloid malignancies: mutations, models and management
@nl
P2093
P2860
P921
P3181
P356
P1433
P1476
Myeloid malignancies: mutations, models and management
@en
P2093
Anne Murati
Daniel Birnbaum
Mandy Brecqueville
Marie-Joelle Mozziconacci
Raynier Devillier
P2860
P2888
P3181
P356
10.1186/1471-2407-12-304
P407
P5008
P577
2012-07-23T00:00:00Z
P5875
P6179
1042181853